NCT07395037

Brief Summary

This multicenter, prospective observational study will evaluate national and international practice variations (if present) in the emergency management of patients admitted to hospital with haematuria, inform a consensus guideline for best practice and provide evidence to design an implementation study to optimise haematuria management pathway.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,050

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2024

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2024

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

March 14, 2025

Completed
11 months until next milestone

First Posted

Study publicly available on registry

February 9, 2026

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2026

Completed
Last Updated

February 9, 2026

Status Verified

February 1, 2026

Enrollment Period

2.3 years

First QC Date

March 14, 2025

Last Update Submit

February 3, 2026

Conditions

Keywords

catheterhaematuriahematuriairrigation

Outcome Measures

Primary Outcomes (1)

  • Length of inpatient stay

    Number of calendar days between the day of admission in the index hospital admission episode and the day of discharge from the hospital.

    At 90 days

Secondary Outcomes (5)

  • Mortality rate

    At 90 days

  • Readmission rate

    At 90 days

  • Time to definitive diagnosis

    At 90 days

  • Number of days alive and out of hospital

    At 90 days.

  • Resource use

    At 90 days

Study Arms (1)

Prospective, obersational cohort (single cohort study)

All patients meeting above defined inclusion and exclusion criteria. This study will take place in urological secondary and tertiary care centres internationally. The study will be conducted in centres that agree to participate in the study and meet the study's inclusion criteria below.

Other: Inpatient work-up and management

Interventions

The study hypothesis is that there is significant international and national variation in the diagnostic workup and management of patients requiring admission to the hospital with haematuria. Increased length of stay and poor outcomes in terms of mortality and healthcare costs are associated with management practices. The CRF will collect datapoints on inpatient work-up and management.

Prospective, obersational cohort (single cohort study)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients will be included consecutively if they are over 18 years of age and admitted to a participating secondary care centre as an emergency with haematuria under the primary or joint care of the urology team.

You may qualify if:

  • Patients are included if they are over 16 years of age or older and admitted to a participating urological secondary care centre
  • admitted as an emergency with haematuria as the primary or secondary diagnosis under the primary or joint care of urology

You may not qualify if:

  • any patients under 16 years of age
  • patients with catheter-related urethral trauma (defined as haemturia immediately after insertion of a urethral catheter that was documented as traumatic by the clinician, with no previous history of haemturia prior to catheter insertion)
  • patients that are in hospital less than 24 hours.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

BURST

London, United Kingdom

RECRUITING

Related Links

MeSH Terms

Conditions

Urologic DiseasesHematuriaUrinary Bladder NeoplasmsKidney NeoplasmsCarcinoma, Transitional Cell

Interventions

Therapeutics

Condition Hierarchy (Ancestors)

Female Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesUrination DisordersHemorrhagePathologic ProcessesPathological Conditions, Signs and SymptomsUrologic NeoplasmsUrogenital NeoplasmsNeoplasms by SiteNeoplasmsUrinary Bladder DiseasesKidney DiseasesCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic Type

Central Study Contacts

Kevin Byrnes, PhD

CONTACT

Nikita Bhatt, FRCS

CONTACT

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 14, 2025

First Posted

February 9, 2026

Study Start

January 1, 2024

Primary Completion

April 30, 2026

Study Completion

April 30, 2026

Last Updated

February 9, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will not share

Locations